Vistagen Therapeutics (VTGN) Raised to Buy at ValuEngine

ValuEngine upgraded shares of Vistagen Therapeutics (NASDAQ:VTGN) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

VTGN has been the topic of several other reports. Maxim Group set a $6.00 target price on shares of Vistagen Therapeutics and gave the company a buy rating in a research report on Wednesday, October 3rd. Oppenheimer set a $6.00 target price on shares of Vistagen Therapeutics and gave the company a buy rating in a research report on Friday, August 24th. Finally, Zacks Investment Research upgraded shares of Vistagen Therapeutics from a hold rating to a buy rating and set a $1.50 target price on the stock in a research report on Thursday, August 30th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Vistagen Therapeutics currently has an average rating of Buy and an average target price of $8.30.

Shares of NASDAQ VTGN opened at $2.10 on Thursday. Vistagen Therapeutics has a 12-month low of $0.69 and a 12-month high of $2.65.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Monday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.13). As a group, equities research analysts forecast that Vistagen Therapeutics will post -0.75 earnings per share for the current year.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

See Also: Hedge Funds – Risk or Reward?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply